{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:28:22Z","timestamp":1786998502989,"version":"build-2736575974"},"reference-count":174,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NIH"},{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sanofi-Genzyme"},{"DOI":"10.13039\/100014275","name":"Parkinson Study Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007059","name":"Northwestern University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007059","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sanofi-Genzyme"},{"name":"Takeda-Shire"},{"name":"Lysosomal Disease Network","award":["U54NS065768"],"award-info":[{"award-number":["U54NS065768"]}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"publisher","award":["UL1TR002494"],"award-info":[{"award-number":["UL1TR002494"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ymgme.2019.10.006","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T12:54:14Z","timestamp":1571835254000},"page":"35-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["GBA1 mutations: Prospects for exosomal biomarkers in \u03b1-synuclein pathologies"],"prefix":"10.1016","volume":"129","author":[{"given":"Parker H.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal J.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Cloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Tuite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena V.","family":"Kartha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2019.10.006_bb0005","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.256.5058.794","article-title":"Gaucher disease: new molecular approaches to diagnosis and treatment","volume":"256","author":"Beutler","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0010","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher's disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0015","series-title":"GeneReviews\u00ae","article-title":"Gaucher disease","author":"Pastores","year":"1993"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/10245332.2016.1240391","article-title":"Gaucher disease epidemiology and natural history: a comprehensive review of the literature","volume":"22","author":"Nalysnyk","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0025","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jmg.2004.024455","article-title":"Parkinsonism among Gaucher disease carriers","volume":"41","author":"Goker-Alpan","year":"2004","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0030","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ane.12247","article-title":"Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease \u2013 a systematic review","volume":"130","author":"Malek","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0040","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41593-019-0423-2","article-title":"Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes","volume":"22","author":"Shahmoradian","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0045","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pneurobio.2019.01.005","article-title":"New windows into the brain: central nervous system-derived extracellular vesicles in blood","volume":"175","author":"Shi","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0050","first-page":"411","article-title":"Glucocerebrosidase mutations in Parkinson disease","volume":"7","author":"O'Regan","year":"2017","journal-title":"J. Park. Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0055","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s10545-008-0868-z","article-title":"Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry","volume":"31","author":"Fairley","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020441","article-title":"A review of gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0065","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1086\/302925","article-title":"Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease","volume":"66","author":"Koprivica","year":"2000","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0070","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnmol.2018.00043","article-title":"Integrated genetic analysis of racial differences of common GBA variants in Parkinson's disease: a meta-analysis","volume":"11","author":"Zhang","year":"2018","journal-title":"Front. Mol. Neurosci."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2019.10.006_bb0075","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jnc.13385","article-title":"The relationship between glucocerebrosidase mutations and Parkinson disease","volume":"139","author":"Migdalska-Richards","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0080","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0950-3536(97)80037-6","article-title":"Gaucher's disease. Pathological features","volume":"10","author":"Pastores","year":"1997","journal-title":"Baillieres Clin. Haematol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0085","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/qjmed\/89.9.691","article-title":"Occurrence of Parkinson's syndrome in type I Gaucher disease","volume":"89","author":"Neudorfer","year":"1996","journal-title":"QJM"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0090","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.WNL.0000072482.70963.D7","article-title":"Gaucher's disease with Parkinson's disease: clinical and pathological aspects","volume":"61","author":"Bembi","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0095","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/(SICI)1096-8652(199907)61:3<216::AID-AJH12>3.0.CO;2-B","article-title":"Parkinson's syndrome preceding clinical manifestation of Gaucher's disease","volume":"61","author":"Machaczka","year":"1999","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0100","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ymgme.2003.11.004","article-title":"Glucocerebrosidase mutations in subjects with parkinsonism","volume":"81","author":"Lwin","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0105","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMoa033277","article-title":"Mutations in the glucocerebrosidase gene and Parkinson\u2019s disease in Ashkenazi Jews","volume":"351","author":"Aharon-Peretz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0110","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.bcmd.2006.02.004","article-title":"Increased incidence of Parkinson disease among relatives of patients with Gaucher disease","volume":"36","author":"Halperin","year":"2006","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0115","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/brain\/awp044","article-title":"Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease","volume":"132","author":"Neumann","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0120","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/mgme.2001.3201","article-title":"Gaucher disease and parkinsonism: a phenotypic and genotypic characterization","volume":"73","author":"Tayebi","year":"2001","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0130","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs mild GBA mutations on Parkinson disease","volume":"84","author":"Gan-Or","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0135","first-page":"916971","article-title":"Effect of GBA mutations on phenotype of Parkinson\u2019s Disease: a study on Chinese population and a meta-analysis","volume":"2015","author":"Zhang","year":"2015","journal-title":"Park. Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0140","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.wnl.0000276989.17578.02","article-title":"Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease","volume":"69","author":"Clark","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0145","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s00415-013-7011-2","article-title":"Clinical, genetic, and brain sonographic features related to Parkinson\u2019s disease in Gaucher disease","volume":"260","author":"B\u00f6ttcher","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0150","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1016\/j.neurobiolaging.2015.08.027","article-title":"Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson\u2019s disease","volume":"36","author":"Oeda","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0155","first-page":"31","article-title":"Cognitive and antipsychotic medication use in monoallelic GBA-related Parkinson disease","volume":"16","author":"Barrett","year":"2014","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2018.05.009","article-title":"Parkinson\u2019s disease phenotype is influenced by the severity of the mutations in the GBA gene","author":"Thaler","year":"2018","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0165","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ana.24777","article-title":"Survival and dementia in GBA-associated Parkinson\u2019s disease: the mutation matters","volume":"80","author":"Cilia","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0170","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","article-title":"The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry","volume":"46","author":"Rosenbloom","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0175","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3389\/fneur.2018.00295","article-title":"Alpha-synuclein: from early synaptic dysfunction to neurodegeneration","volume":"9","author":"Ghiglieri","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0180","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbrc.2007.04.108","article-title":"Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson\u2019s disease, in erythropoietic lineage","volume":"358","author":"Nakai","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0185","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neulet.2010.06.009","article-title":"Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson\u2019s disease","volume":"480","author":"Shi","year":"2010","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0190","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbadis.2011.10.002","article-title":"\u0391-synuclein misfolding and Parkinson\u2019s disease","volume":"1822","author":"Breydo","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0195","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol."},{"issue":"36","key":"10.1016\/j.ymgme.2019.10.006_bb0200","article-title":"Silencing alpha synuclein in mature nigral neurons results in rapid neuroinflammation and subsequent toxicity","volume":"11","author":"Benskey","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dadm.2017.08.003","article-title":"The effects of apolipoprotein E genotype, \u03b1-synuclein deficiency, and sex on brain synaptic and Alzheimer\u2019s disease-related pathology","volume":"10","author":"Bar","year":"2018","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0210","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0896-6273(00)80886-7","article-title":"Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system","volume":"25","author":"Abeliovich","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0215","doi-asserted-by":"crossref","DOI":"10.1177\/1073858417748875","article-title":"Glucocerebrosidase and Parkinson disease: molecular, clinical, and therapeutic implications","author":"Balestrino","year":"2018","journal-title":"Neuroscientist"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0220","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.22400","article-title":"Acid \u03b2-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter \u03b1-synuclein processing","volume":"69","author":"Cullen","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0225","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0230","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.neuro.2009.06.009","article-title":"Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism","volume":"30","author":"Manning-Bo\u011f","year":"2009","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0235","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1038\/emm.2014.128","article-title":"Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and \u03b1-synuclein aggregation","volume":"47","author":"Bae","year":"2015","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0240","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1089\/ars.2015.6307","article-title":"Sustained systemic glucocerebrosidase inhibition induces brain \u03b1-synuclein aggregation, microglia and complement C1q activation in mice","volume":"23","author":"Rocha","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0245","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1073\/pnas.1220464110","article-title":"Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies","volume":"110","author":"Sardi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0250","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.nbd.2015.09.009","article-title":"Glucocerebrosidase gene therapy prevents \u03b1-synucleinopathy of midbrain dopamine neurons","volume":"82","author":"Rocha","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0255","first-page":"769","article-title":"A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease","volume":"9","author":"Westbroek","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0260","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/hmg\/ddt468","article-title":"Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration","volume":"23","author":"Farfel-Becker","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0265","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","article-title":"Glucosylsphingosine promotes \u03b1-synuclein pathology in mutant GBA-associated Parkinson\u2019s disease","volume":"37","author":"Taguchi","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0270","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1074\/jbc.C100560200","article-title":"The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein","volume":"277","author":"Manning-Bog","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0275","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1523\/JNEUROSCI.2954-10.2011","article-title":"Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Abeta generation","volume":"31","author":"Tamboli","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0280","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/mds.26278","article-title":"No evidence for substrate accumulation in Parkinson brains with GBA mutations","volume":"30","author":"Gegg","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0285","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1038\/ncomms5028","article-title":"iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis","volume":"5","author":"Sch\u00f6ndorf","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0290","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.stemcr.2016.01.013","article-title":"ER stress and autophagic perturbations lead to elevated extracellular \u03b1-synuclein in GBA-N370S Parkinson\u2019s iPSC-derived dopamine neurons","volume":"6","author":"Fernandes","year":"2016","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0295","series-title":"Glucosylceramide Blood Test for GBA-associated Parkinson\u2019s Disease: A Potential Companion For Precision Therapeutics","author":"Sardi","year":"2019"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0300","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/acn3.177","article-title":"Progressive decline of glucocerebrosidase in aging and Parkinson\u2019s disease","volume":"2","author":"Rocha","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0305","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/hmg\/ddy105","article-title":"Acid ceramidase inhibition ameliorates \u03b1-synuclein accumulation upon loss of GBA1 function","volume":"27","author":"Kim","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0310","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","article-title":"ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity","volume":"14","author":"Ron","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0315","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1093\/hmg\/ddq292","article-title":"Interaction between parkin and mutant glucocerebrosidase variants: a possible link between Parkinson disease and Gaucher disease","volume":"19","author":"Ron","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0320","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1750-1172-9-86","article-title":"Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS","volume":"9","author":"Bendikov-Bar","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0325","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bcmd.2010.10.012","article-title":"Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant","volume":"46","author":"Bendikov-Bar","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0330","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ceca.2015.11.002","article-title":"Endoplasmic reticulum and lysosomal Ca2+ stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts","volume":"59","author":"Kilpatrick","year":"2016","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0335","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00401-010-0741-7","article-title":"Glucocerebrosidase is present in \u03b1-synuclein inclusions in Lewy body disorders","volume":"120","author":"Goker-Alpan","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0340","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1212\/01.wnl.0000304039.11891.29","article-title":"Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset","volume":"70","author":"Gan-Or","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0345","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/brain\/awv179","article-title":"Glucocerebrosidase activity in Parkinson\u2019s disease with and without GBA mutations","volume":"138","author":"Alcalay","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0350","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased \u03b1-synuclein in sporadic Parkinson\u2019s disease","volume":"137","author":"Murphy","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0355","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neulet.2016.10.039","article-title":"Oligomeric \u03b1-synuclein and glucocerebrosidase activity levels in GBA-associated Parkinson\u2019s disease","volume":"636","author":"Pchelina","year":"2017","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0360","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/mds.26200","article-title":"Plasma oligomeric alpha-synuclein is associated with glucocerebrosidase activity in Gaucher disease","volume":"30","author":"Nuzhnyi","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0365","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s13311-014-0294-x","article-title":"A GCase chaperone improves motor function in a mouse model of synucleinopathy","volume":"11","author":"Richter","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0370","first-page":"2645","article-title":"Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson\u2019s disease","volume":"25","author":"Rockenstein","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0375","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/mds.26433","article-title":"Lysosomal alterations in peripheral blood mononuclear cells of Parkinson\u2019s disease patients","volume":"30","author":"Papagiannakis","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0380","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.parkreldis.2015.12.002","article-title":"Leukocyte glucocerebrosidase and \u03b2-hexosaminidase activity in sporadic and genetic Parkinson disease","volume":"23","author":"Kim","year":"2016","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0385","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.nbd.2018.01.012","article-title":"Alpha galactosidase A activity in Parkinson\u2019s disease","volume":"112","author":"Alcalay","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0390","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1093\/brain\/awx285","article-title":"Excessive burden of lysosomal storage disorder gene variants in Parkinson\u2019s disease","volume":"140","author":"Robak","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/diseases4040031","article-title":"Mitochondrial dysfunction in lysosomal storage disorders","volume":"4","author":"de la Mata","year":"2016","journal-title":"Diseases"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0400","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/hmg\/ddu538","article-title":"Glucocerebrosidase deficiency in zebrafish affects primary bone ossification through increased oxidative stress and reduced Wnt\/\u03b2-catenin signaling","volume":"24","author":"Zancan","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0405","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1517\/14728221003652489","article-title":"Targeting mitochondrial dysfunction in neurodegenerative disease: part I","volume":"14","author":"Burchell","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0410","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.abb.2007.03.034","article-title":"Selective degradation of mitochondria by mitophagy","volume":"462","author":"Kim","year":"2007","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0415","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.4161\/auto.25878","article-title":"Defective quality control mechanisms and accumulation of damaged mitochondria link Gaucher and Parkinson diseases","volume":"9","author":"Osellame","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0420","doi-asserted-by":"crossref","first-page":"21490","DOI":"10.1074\/jbc.M113.545749","article-title":"Soluble, prefibrillar \u03b1-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction","volume":"289","author":"Luth","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0425","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/jnen\/nly024","article-title":"Increased oxidative stress exacerbates \u03b1-synuclein aggregation in vivo","volume":"77","author":"Scudamore","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0430","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.nbd.2015.09.006","article-title":"Mitochondrial dysfunction associated with glucocerebrosidase deficiency","volume":"90","author":"Gegg","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0435","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1474-4422(05)70285-4","article-title":"The diagnosis of Parkinson\u2019s disease","volume":"5","author":"Tolosa","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0440","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/mds.26562","article-title":"Lysosomal dysfunction and \u03b1-synuclein aggregation in Parkinson\u2019s disease: diagnostic links","volume":"31","author":"Moors","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0445","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neulet.2012.11.004","article-title":"Total CSF \u03b1-synuclein is lower in de novo Parkinson patients than in healthy subjects","volume":"532","author":"Mollenhauer","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0450","first-page":"1277","article-title":"Association of cerebrospinal fluid \u03b2-amyloid 1-42, T-tau, P-tau181, and \u03b1-synuclein levels with clinical features of drug-naive patients with early Parkinson disease","volume":"70","author":"Kang","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0455","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/brain\/awq008","article-title":"DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson\u2019s disease","volume":"133","author":"Hong","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0460","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neulet.2008.11.015","article-title":"Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?","volume":"450","author":"Ohrfelt","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0465","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3988\/jcn.2011.7.4.215","article-title":"Elevated levels of \u03b1-synuclein oligomer in the cerebrospinal fluid of drug-na\u00efve patients with Parkinson\u2019s disease","volume":"7","author":"Park","year":"2011","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0470","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.nbd.2011.08.003","article-title":"Post mortem cerebrospinal fluid \u03b1-synuclein levels are raised in multiple system atrophy and distinguish this from the other \u03b1-synucleinopathies, Parkinson\u2019s disease and dementia with Lewy bodies","volume":"45","author":"Foulds","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0475","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3109\/00207454.2014.961454","article-title":"Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson\u2019s disease diagnosis: a systematic review and meta-analysis","volume":"125","author":"Gao","year":"2015","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0480","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052312","article-title":"\u0391lpha-synuclein levels in blood plasma from LRRK2 mutation carriers","volume":"7","author":"Gorostidi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0485","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/mds.22928","article-title":"Plasma alpha-synuclein in patients with Parkinson\u2019s disease with and without treatment","volume":"25","author":"Duran","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0490","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00702-005-0427-9","article-title":"The plasma alpha-synuclein levels in patients with Parkinson\u2019s disease and multiple system atrophy","volume":"113","author":"Lee","year":"2006","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0495","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1038\/srep02540","article-title":"A longitudinal study on \u03b1-synuclein in blood plasma as a biomarker for Parkinson\u2019s disease","volume":"3","author":"Foulds","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0500","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1096\/fj.10-179192","article-title":"Phosphorylated \u03b1-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson\u2019s disease","volume":"25","author":"Foulds","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0505","article-title":"The relation between plasma \u03b1-synuclein level and clinical symptoms or signs of Parkinson\u2019s disease","author":"Malec-Litwinowicz","year":"2017","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0510","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00702-013-0972-6","article-title":"Gender differences in Parkinson\u2019s disease: focus on plasma \u03b1-synuclein","volume":"120","author":"Caranci","year":"2013","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0515","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1096\/fj.03-1449com","article-title":"Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson\u2019s disease","volume":"20","author":"El-Agnaf","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0520","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000112832","article-title":"Red blood cells are the major source of alpha-synuclein in blood","volume":"5","author":"Barbour","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0525","doi-asserted-by":"crossref","first-page":"13713","DOI":"10.1038\/s41598-017-14175-5","article-title":"Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson\u2019s disease","volume":"7","author":"Vicente Miranda","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0530","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neulet.2015.05.030","article-title":"Detection of \u03b1-synuclein oligomers in red blood cells as a potential biomarker of Parkinson\u2019s disease","volume":"599","author":"Wang","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0535","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.neulet.2014.09.041","article-title":"Increased plasma oligomeric alpha-synuclein in patients with lysosomal storage diseases","volume":"583","author":"Pchelina","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0540","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neulet.2017.11.012","article-title":"Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson\u2019s Disease","volume":"672","author":"Papagiannakis","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0545","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.neulet.2012.08.069","article-title":"Increased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging","volume":"528","author":"Argyriou","year":"2012","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0550","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1083\/jcb.201211138","article-title":"Extracellular vesicles: exosomes, microvesicles, and friends","volume":"200","author":"Raposo","year":"2013","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0555","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3389\/fimmu.2014.00403","article-title":"Exosomes and autophagy: coordinated mechanisms for the maintenance of cellular fitness","volume":"5","author":"Baixauli","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0560","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1083\/jcb.201212113","article-title":"Exosomes: looking back three decades and into the future","volume":"200","author":"Harding","year":"2013","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0565","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/19336918.2016.1236899","article-title":"Mechanisms and functions of extracellular vesicle release in vivo-What we can learn from flies and worms","volume":"11","author":"Beer","year":"2017","journal-title":"Cell Adhes. Migr."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0570","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fnins.2017.00278","article-title":"Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes","volume":"11","author":"Mustapic","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0575","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.pneurobio.2011.01.003","article-title":"Multivesicular bodies in neurons: distribution, protein content, and trafficking functions","volume":"93","author":"Von Bartheld","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0580","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.cellbio.23.090506.123319","article-title":"Biogenesis and function of multivesicular bodies","volume":"23","author":"Piper","year":"2007","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0585","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ceb.2014.05.004","article-title":"Biogenesis and secretion of exosomes","volume":"29","author":"Kowal","year":"2014","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0590","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201800149","article-title":"Exosomes in inflammation and inflammatory disease","author":"Chan","year":"2019","journal-title":"Proteomics"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0595","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1902513116","article-title":"Exosomes regulate neurogenesis and circuit assembly","author":"Sharma","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0600","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s12035-013-8544-1","article-title":"Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics","volume":"49","author":"Kalani","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0605","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jalz.2014.06.008","article-title":"Identification of preclinical Alzheimer\u2019s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study","volume":"11","author":"Fiandaca","year":"2015","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0610","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1096\/fj.14-262048","article-title":"Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer\u2019s disease","volume":"29","author":"Kapogiannis","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0615","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/WNL.0000000000001702","article-title":"Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease","volume":"85","author":"Goetzl","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0620","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aau4543","article-title":"Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of \u03b1-synuclein","volume":"12","author":"Harischandra","year":"2019","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0625","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2018.4304","article-title":"Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson Disease: a secondary analysis of the exenatide-PD trial","author":"Athauda","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0630","doi-asserted-by":"crossref","first-page":"789","DOI":"10.7150\/thno.18133","article-title":"Progress in exosome isolation techniques","volume":"7","author":"Li","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0635","doi-asserted-by":"crossref","first-page":"13010","DOI":"10.1073\/pnas.0903691106","article-title":"Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein","volume":"106","author":"Desplats","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0640","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40478-015-0198-y","article-title":"Neuron-to-neuron \u03b1-synuclein propagation in vivo is independent of neuronal injury","volume":"3","author":"Ulusoy","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0645","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological \u03b1-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0650","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.1523\/JNEUROSCI.0692-05.2005","article-title":"Intravesicular localization and exocytosis of alpha-synuclein and its aggregates","volume":"25","author":"Lee","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0655","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1074\/jbc.M114.585703","article-title":"Acceleration of \u03b1-synuclein aggregation by exosomes","volume":"290","author":"Grey","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"42","key":"10.1016\/j.ymgme.2019.10.006_bb0660","article-title":"Exosomal cell-to-cell transmission of alpha synuclein oligomers","volume":"7","author":"Danzer","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0665","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.nbd.2011.01.029","article-title":"Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission","volume":"42","author":"Alvarez-Erviti","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0670","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.arr.2016.05.001","article-title":"Impact of lysosome status on extracellular vesicle content and release","volume":"32","author":"Eitan","year":"2016","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0675","first-page":"1696","article-title":"Modulation of \u03b2-glucocerebrosidase increases \u03b1-synuclein secretion and exosome release in mouse models of Parkinson\u2019s disease","volume":"27","author":"Papadopoulos","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0680","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1038\/ncomms5755","article-title":"Glucocerebrosidase depletion enhances cell-to-cell transmission of \u03b1-synuclein","volume":"5","author":"Bae","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0685","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1007694","article-title":"Glucocerebrosidase deficiency promotes protein aggregation through dysregulation of extracellular vesicles","volume":"14","author":"Thomas","year":"2018","journal-title":"PLoS Genet."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0690","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/mds.23455","article-title":"Glia: initiators and progressors of pathology in Parkinson\u2019s disease","volume":"26","author":"Halliday","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0695","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neulet.2013.06.009","article-title":"Exosomes of BV-2 cells induced by alpha-synuclein: important mediator of neurodegeneration in PD","volume":"548","author":"Chang","year":"2013","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0700","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2011.07.002","article-title":"Inflammation in the early stages of neurodegenerative pathology","volume":"238","author":"Khandelwal","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0705","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1523\/JNEUROSCI.5427-08.2009","article-title":"Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy","volume":"29","author":"Chung","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0710","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00401-014-1314-y","article-title":"Plasma exosomal \u03b1-synuclein is likely CNS-derived and increased in Parkinson\u2019s disease","volume":"128","author":"Shi","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0715","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fnagi.2018.00438","article-title":"Increased DJ-1 and \u03b1-synuclein in plasma neural-derived exosomes as potential markers for Parkinson\u2019s disease","volume":"10","author":"Zhao","year":"2018","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0720","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fncel.2018.00125","article-title":"The exosomal\/total \u03b1-synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients","volume":"12","author":"Cerri","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroscience.2019.05.015","article-title":"Central nervous system-derived exosomal alpha-synuclein in serum may be a biomarker in Parkinson\u2019s disease","author":"Si","year":"2019","journal-title":"Neuroscience"},{"issue":"52","key":"10.1016\/j.ymgme.2019.10.006_bb0730","article-title":"Glucocerebrosidase mutations and synucleinopathies. potential role of sterylglucosides and relevance of studying both GBA1 and GBA2 genes","volume":"12","author":"Franco","year":"2018","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0735","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bcmd.2012.11.011","article-title":"Phenotype in patients with Gaucher disease and Parkinson disease","volume":"50","author":"Chetrit","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0740","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.expneurol.2010.07.023","article-title":"Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease","volume":"225","author":"Cabrera-Salazar","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0745","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ymgme.2017.12.060","article-title":"Exosome-based delivery of glucocerebrosidase lysosomal enzyme for treatment of Gaucher disease","volume":"123","author":"Choi","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0750","article-title":"Reversible conformational conversion of \u03b1-synuclein into toxic assemblies by glucosylceramide","author":"Zunke","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0755","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1073\/pnas.1700465115","article-title":"GBA1 deficiency negatively affects physiological \u03b1-synuclein tetramers and related multimers","volume":"115","author":"Kim","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0760","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1194\/jlr.M021261","article-title":"Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain","volume":"53","author":"Larsen","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0765","first-page":"947","article-title":"Substrate reduction therapy in mouse models of the glycosphingolipidoses","volume":"358","author":"Platt","year":"2003","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0770","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/mt.2016.53","article-title":"CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0775","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.27414","article-title":"Targeted therapies for Parkinson\u2019s disease: from genetics to the clinic","volume":"33","author":"Sardi","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0780","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nchembio850","article-title":"Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease","volume":"3","author":"Lieberman","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0785","doi-asserted-by":"crossref","first-page":"13192","DOI":"10.1073\/pnas.0705637104","article-title":"Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease","volume":"104","author":"Zheng","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0790","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/14789450.2016.1174583","article-title":"Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease","volume":"13","author":"Jung","year":"2016","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0795","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1742-4658.2010.07588.x","article-title":"The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase","volume":"277","author":"Khanna","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0800","article-title":"Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse","volume":"6","author":"Sun","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0805","doi-asserted-by":"crossref","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","article-title":"Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease","volume":"284","author":"Maegawa","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0810","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0815","doi-asserted-by":"crossref","first-page":"31380","DOI":"10.1038\/srep31380","article-title":"Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models","volume":"6","author":"Sanchez-Martinez","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0820","doi-asserted-by":"crossref","DOI":"10.1002\/syn.21967","article-title":"Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate","volume":"71","author":"Migdalska-Richards","year":"2017","journal-title":"Synapse"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0825","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.bcmd.2012.09.006","article-title":"Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease","volume":"50","author":"Zimran","year":"2013","journal-title":"Blood Cell Mol. Dis."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0830","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0835","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/s41598-018-19479-8","article-title":"Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons","volume":"8","author":"Magalhaes","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0840","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.stemcr.2017.01.011","article-title":"A human neural crest stem cell-derived dopaminergic neuronal model recapitulates biochemical abnormalities in GBA1 mutation carriers","volume":"8","author":"Yang","year":"2017","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0845","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029861","article-title":"High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase","volume":"7","author":"Goldin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2019.10.006_bb0850","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A new glucocerebrosidase chaperone reduces \u03b1-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and Parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0855","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","article-title":"Activation of \u03b2-glucocerebrosidase reduces pathological \u03b1-synuclein and restores lysosomal function in Parkinson\u2019s patient midbrain neurons","volume":"36","author":"Mazzulli","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0860","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008659","article-title":"Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs","volume":"6","author":"Aflaki","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0865","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/mt.2012.152","article-title":"Pharmacological enhancement of \u03b1-glucosidase by the allosteric chaperone N-acetylcysteine","volume":"20","author":"Porto","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2019.10.006_bb0870","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.ymgme.2016.11.175","article-title":"Role of oxidative stress and inflammation in type 1 Gaucher disease (GD1): Potential use of antioxidant\/anti-inflammatory medications","volume":"120","author":"Kartha","year":"2017","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719219301477?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719219301477?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:25:15Z","timestamp":1761089115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719219301477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":174,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1096719219301477"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.10.006","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GBA1 mutations: Prospects for exosomal biomarkers in \u03b1-synuclein pathologies","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}